|
1
|
Ezzat S, Asa SL, Couldwell WT, Barr CE,
Dodge WE, Vance ML and McCutcheon IE: The prevalence of pituitary
adenomas: A systematic review. Cancer. 101:613–619. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Melmed S: Pathogenesis of pituitary
tumors. Nat Rev Endocrinol. 7:257–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Horn K, Erhardt F, Fahlbusch R, Pickardt
CR, Werder KV and Scriba PC: Recurrent goiter, hyperthyroidism,
galactorrhea and amenorrhea due to a thyrotropin and
prolactin-producing pituitary tumor. J Clin Endocrinol Metab.
43:137–143. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dusek T, Kastelan D, Melada A, Baretic M,
Skoric Polovina T, Perkovic Z, Giljevic Z, Jelcic J, Paladino J,
Aganovic I, et al: Clinical features and therapeutic outcomes of
patients with acromegaly: Single-center experience. J Endocrinol
Invest. 34:e382–e385. 2011.PubMed/NCBI
|
|
5
|
Hofstetter CP, Mannaa RH, Mubita L, Anand
VK, Kennedy JW, Dehdashti AR and Schwartz TH: Endoscopic endonasal
transsphenoidal surgery for growth hormone-secreting pituitary
adenomas. Neurosurg Focus. 29:E62010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tabaee A, Anand VK, Barrón Y, Hiltzik DH,
Brown SM, Kacker A, Mazumdar M and Schwartz TH: Endoscopic
pituitary surgery: A systematic review and meta-analysis. J
Neurosurg. 111:545–554. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Herr P, Hausmann G and Basler K: WNT
secretion and signalling in human disease. Trends Mol Med.
18:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gueorguiev M and Grossman AB: Pituitary
gland and beta-catenin signaling: From ontogeny to oncogenesis.
Pituitary. 12:245–255. 2009. View Article : Google Scholar
|
|
11
|
Gueorguiev M and Grossman AB: Pituitary
tumors in 2010: A new therapeutic era for pituitary tumors. Nat Rev
Endocrinol. 7:71–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cruciat CM and Niehrs C: Secreted and
transmembrane wnt inhibitors and activators. Cold Spring Harb
Perspect Biol. 5:a0150812013. View Article : Google Scholar
|
|
13
|
Constantinou T, Baumann F, Lacher MD,
Saurer S, Friis R and Dharmarajan A: SFRP-4 abrogates
Wnt-3a-induced beta-catenin and Akt/PKB signalling and reverses a
Wnt-3a-imposed inhibition of in vitro mammary differentiation. J
Mol Signal. 3:102008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Longman D, Arfuso F, Viola HM, Hool LC and
Dharmarajan AM: The role of the cysteine-rich domain and
netrin-like domain of secreted frizzled-related protein 4 in
angiogenesis inhibition in vitro. Oncol Res. 20:1–6. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Froeling FE, Feig C, Chelala C, Dobson R,
Mein CE, Tuveson DA, Clevers H, Hart IR and Kocher HM: Retinoic
acid-induced pancreatic stellate cell quiescence reduces paracrine
Wnt-beta-catenin signaling to slow tumor progression.
Gastroenterology. 141:1486–1497. 2011. View Article : Google Scholar
|
|
16
|
Granados-Principal S, Quiles JL,
Ramirez-Tortosa C, Camacho-Corencia P, Sanchez-Rovira P,
Vera-Ramirez L and Ramirez-Tortosa MC: Hydroxytyrosol inhibits
growth and cell proliferation and promotes high expression of sfrp4
in rat mammary tumours. Mol Nutr Food Res. 55(Suppl 1): S117–S126.
2011. View Article : Google Scholar
|
|
17
|
Frank B, Hoffmeister M, Klopp N, Illig T,
Chang-Claude J and Brenner H: Single nucleotide polymorphisms in
Wnt signaling and cell death pathway genes and susceptibility to
colorectal cancer. Carcinogenesis. 31:1381–1386. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hrzenjak A, Tippl M, Kremser ML,
Strohmeier B, Guelly C, Neumeister D, Lax S, Moinfar F, Tabrizi AD,
Isadi-Moud N, et al: Inverse correlation of secreted
frizzled-related protein 4 and beta-catenin expression in
endometrial stromal sarcomas. J Pathol. 204:19–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Hurley G, Perry AS, O'Grady A, Loftus B,
Smyth P, O'Leary JJ, Sheils O, Fitzpatrick JM, Hewitt SM, Lawler M,
et al: The role of secreted frizzled-related protein 2 expression
in prostate cancer. Histopathology. 59:1240–1248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saran U, Arfuso F, Zeps N and Dharmarajan
A: Secreted frizzled-related protein 4 expression is positively
associated with responsiveness to cisplatin of ovarian cancer cell
lines in vitro and with lower tumour grade in mucinous ovarian
cancers. BMC Cell Biol. 13:252012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marsit CJ, Karagas MR, Andrew A, Liu M,
Danaee H, Schned AR, Nelson HH and Kelsey KT: Epigenetic
inactivation of SFRP genes and TP53 alteration act jointly as
markers of invasive bladder cancer. Cancer Res. 65:7081–7085. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi J, Zhu YQ, Luo J and Tao WH:
Hypermethylation and expression regulation of secreted
frizzled-related protein genes in colorectal tumor. World J
Gastroenterol. 12:7113–7117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chung MT, Lai HC, Sytwu HK, Yan MD, Shih
YL, Chang CC, Yu MH, Liu HS, Chu DW and Lin YW: SFRP1 and SFRP2
suppress the transformation and invasion abilities of cervical
cancer cells through Wnt signal pathway. Gynecol Oncol.
112:646–653. 2009. View Article : Google Scholar
|
|
24
|
Elston MS, Gill AJ, Conaglen JV, Clarkson
A, Shaw JM, Law AJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson
BG, et al: Wnt pathway inhibitors are strongly down-regulated in
pituitary tumors. Endocrinology. 149:1235–1242. 2008. View Article : Google Scholar
|
|
25
|
Hong L, Wu Y, Feng J, Yu S, Li C, Wu Y, Li
Z, Cao L, Wang F and Zhang Y: Overexpression of the cell adhesion
molecule claudin-9 is associated with invasion in pituitary
oncocytomas. Hum Pathol. 45:2423–2429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu Y, Bai J, Li Z, Wang F, Cao L, Liu C,
Yu S, Yu G and Zhang Y: Low expression of secreted frizzled-related
protein 4 in aggressive pituitary adenoma. Pituitary. 18:335–342.
2015. View Article : Google Scholar
|
|
27
|
Choi JD and Lee JS: Interplay between
epigenetics and genetics in Cancer. Genomics Inform. 11:164–173.
2013. View Article : Google Scholar
|
|
28
|
Kinoshita T, Nomoto S, Kodera Y, Koike M,
Fujiwara M and Nakao A: Decreased expression and aberrant
hypermethylation of the SFRP genes in human gastric cancer.
Hepatogastroenterology. 58:1051–1056. 2011.PubMed/NCBI
|
|
29
|
Urakami S, Shiina H, Enokida H, Kawakami
T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M,
et al: Combination analysis of hypermethylated Wnt-antagonist
family genes as a novel epigenetic biomarker panel for bladder
cancer detection. Clin Cancer Res. 12:2109–2116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu TH, Raval A, Chen SS, Matkovic JJ,
Byrd JC and Plass C: CpG island methylation and expression of the
secreted frizzled-related protein gene family in chronic
lymphocytic leukemia. Cancer Res. 66:653–658. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perry AS, O'Hurley G, Raheem OA, Brennan
K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan
L, et al: Gene expression and epigenetic discovery screen reveal
methylation of SFRP2 in prostate cancer. Int J Cancer.
132:1771–1780. 2013. View Article : Google Scholar
|
|
32
|
Kawakami K, Yamamura S, Hirata H, Ueno K,
Saini S, Majid S, Tanaka Y, Kawamoto K, Enokida H, Nakagawa M, et
al: Secreted frizzled-related protein-5 is epigenetically
downregulated and functions as a tumor suppressor in kidney cancer.
Int J Cancer. 128:541–550. 2011. View Article : Google Scholar
|
|
33
|
Zhang YW, Miao YF, Yi J, Geng J, Wang R
and Chen LB: Transcriptional inactivation of secreted
frizzled-related protein 1 by promoter hypermethylation as a
potential biomarker for non-small cell lung cancer. Neoplasma.
57:228–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Su HY, Lai HC, Lin YW, Liu CY, Chen CK,
Chou YC, Lin SP, Lin WC, Lee HY and Yu MH: Epigenetic silencing of
SFRP5 is related to malignant phenotype and chemoresistance of
ovarian cancer through Wnt signaling pathway. Int J Cancer.
127:555–567. 2010. View Article : Google Scholar
|
|
35
|
Suzuki H, Watkins DN, Jair KW, Schuebel
KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van
Engeland M, et al: Epigenetic inactivation of SFRP genes allows
constitutive WNT signaling in colorectal cancer. Nat Genet.
36:417–422. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
37
|
Zhao P, Wang H, Gao H, Li C and Zhang Y:
Reversal of multidrug resistance by magnetic
chitosan-Fe3O4 nanoparticle-encapsulated
MDR1 siRNA in glioblastoma cell line. Neurol Res.
35:821–828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Horvath LG, Lelliott JE, Kench JG, Lee CS,
Williams ED, Saunders DN, Grygiel JJ, Sutherland RL and Henshall
SM: Secreted frizzled-related protein 4 inhibits proliferation and
metastatic potential in prostate cancer. Prostate. 67:1081–1090.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Páez D, Gerger A, Zhang W, Yang D, Labonte
MJ, Benhanim L, Kahn M, Lenz F, Lenz C, Ning Y, et al: Association
of common gene variants in the WNT/β-catenin pathway with colon
cancer recurrence. Pharmacogenomics J. 14:142–150. 2014. View Article : Google Scholar
|
|
40
|
Yip PY, Kench JG, Rasiah KK, Benito RP,
Lee CS, Stricker PD, Henshall SM, Sutherland RL and Horvath LG: Low
AZGP1 expression predicts for recurrence in margin-positive,
localized prostate cancer. Prostate. 71:1638–1645. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shimon I, Cohen ZR, Ram Z and Hadani M:
Transsphenoidal surgery for acromegaly: endocrinological follow-up
of 98 patients. Neurosurgery. 48:1239–1243; discussion 1244–1235.
2001.PubMed/NCBI
|
|
42
|
Shirvani M and Motiei-Langroudi R:
Transsphenoidal surgery for growth hormone-secreting pituitary
adenomas in 130 patients. World Neurosurg. 81:125–130. 2014.
View Article : Google Scholar
|
|
43
|
Nojima M, Suzuki H, Toyota M, Watanabe Y,
Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K,
et al: Frequent epigenetic inactivation of SFRP genes and
constitutive activation of Wnt signaling in gastric cancer.
Oncogene. 26:4699–4713. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin YW, Chung MT, Lai HC, De Yan M, Shih
YL, Chang CC and Yu MH: Methylation analysis of SFRP genes family
in cervical adenocarcinoma. J Cancer Res Clin Oncol. 135:1665–1674.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shih YL, Hsieh CB, Yan MD, Tsao CM, Hsieh
TY, Liu CH and Lin YW: Frequent concomitant epigenetic silencing of
SOX1 and secreted frizzled-related proteins (SFRPs) in human
hepatocellular carcinoma. J Gastroenterol Hepatol. 28:551–559.
2013. View Article : Google Scholar
|
|
46
|
Botla SK, Gholami AM, Malekpour M,
Moskalev EA, Fallah M, Jandaghi P, Aghajani A, Bondar IS,
Omranipour R, Malekpour F, et al: Diagnostic values of GHSR DNA
methylation pattern in breast cancer. Breast Cancer Res Treat.
135:705–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bu XM, Zhao CH, Zhang N, Gao F, Lin S and
Dai XW: Hypermethylation and aberrant expression of secreted
frizzled-related protein genes in pancreatic cancer. World J
Gastroenterol. 14:3421–3424. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kohno H, Amatya VJ, Takeshima Y, Kushitani
K, Hattori N, Kohno N and Inai K: Aberrant promoter methylation of
WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol Rep. 24:423–431.
2010.PubMed/NCBI
|
|
49
|
Griffiths EA, Gore SD, Hooker C, McDevitt
MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG and Carraway
HE: Acute myeloid leukemia is characterized by Wnt pathway
inhibitor promoter hypermethylation. Leuk Lymphoma. 51:1711–1719.
2010. View Article : Google Scholar : PubMed/NCBI
|
